WINDTREE THERAPEUTICS INC (WINT) Stock Price & Overview

NASDAQ:WINT • US97382D6004

Current stock price

0.11 USD
-0.37 (-77.21%)
At close:
0.1048 USD
-0.01 (-4.73%)
After Hours:

The current stock price of WINT is 0.11 USD. Today WINT is down by -77.21%. In the past month the price decreased by -88.69%. In the past year, price decreased by -99.98%.

WINT Key Statistics

52-Week Range0.1 - 545
Current WINT stock price positioned within its 52-week range.
1-Month Range0.1 - 1.1999
Current WINT stock price positioned within its 1-month range.
Market Cap
3.226M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-400.00
Dividend Yield
N/A

WINT Stock Performance

Today
-77.21%
1 Week
-79.47%
1 Month
-88.69%
3 Months
-85.88%
Longer-term
6 Months -97.47%
1 Year -99.98%
2 Years -99.99%
3 Years -100.00%
5 Years -100.00%
10 Years N/A

WINT Stock Chart

WINDTREE THERAPEUTICS INC / WINT Daily stock chart

WINT Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to WINT. When comparing the yearly performance of all stocks, WINT is a bad performer in the overall market: 99.81% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

WINT Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to WINT. WINT may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

WINT Earnings

Next Earnings DateNov 24, 2025
Last Earnings DateAug 18, 2025
PeriodQ1 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise -100.00%

WINT Forecast & Estimates

6 analysts have analysed WINT and the average price target is 180.54 USD. This implies a price increase of 164027.27% is expected in the next year compared to the current price of 0.11.


Analysts
Analysts43.33
Price Target180.54 (164027.27%)
EPS Next Y84.67%
Revenue Next YearN/A

WINT Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

WINT Financial Highlights

Over the last trailing twelve months WINT reported a non-GAAP Earnings per Share(EPS) of -400. The EPS decreased by -236.14% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-20.75M
Industry RankSector Rank
PM (TTM) N/A
ROA -77.52%
ROE -183.17%
Debt/Equity 0.01
Chartmill High Growth Momentum
EPS Q2Q%-100.42%
Sales Q2Q%N/A
EPS 1Y (TTM)-236.14%
Revenue 1Y (TTM)N/A

WINT Ownership

Ownership
Inst Owners1.23%
Shares29.33M
Float29.33M
Ins Owners0%
Short Float %0.01%
Short Ratio0

About WINT

Company Profile

WINT logo image Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.

Company Info

IPO: 1995-08-09

WINDTREE THERAPEUTICS INC

2600 Kelly Rd Ste 100

Warrington PENNSYLVANIA 18976 US

CEO: Craig E. Fraser

Employees: 14

WINT Company Website

WINT Investor Relations

Phone: 12154889300

WINDTREE THERAPEUTICS INC / WINT FAQ

Can you describe the business of WINDTREE THERAPEUTICS INC?

Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical and medical device company engaged in the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The company is headquartered in Warrington, Pennsylvania and currently employs 14 full-time employees. The firm is engaged in the biotechnology business, advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure and preclinical precision aPKCi inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. aPKCi inhibitor platform is a potential high-potency, specific, drug candidate with applications in oncology, particularly in hedgehog pathway-dependent cancers. The firm also has a licensing business model with partnership out-licenses in place. The firm is also focused on environmental services space.


What is the current price of WINT stock?

The current stock price of WINT is 0.11 USD. The price decreased by -77.21% in the last trading session.


Does WINT stock pay dividends?

WINT does not pay a dividend.


How is the ChartMill rating for WINDTREE THERAPEUTICS INC?

WINT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Which stock exchange lists WINT stock?

WINT stock is listed on the Nasdaq exchange.


Would investing in WINDTREE THERAPEUTICS INC be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on WINT.


What is the market capitalization of WINT stock?

WINDTREE THERAPEUTICS INC (WINT) has a market capitalization of 3.23M USD. This makes WINT a Nano Cap stock.